{"id":"https://openalex.org/W7225757899","doi":"https://doi.org/10.25251/esydg329","title":"Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis","display_name":"Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225757899","doi":"https://doi.org/10.25251/esydg329"},"language":"en","primary_location":{"id":"doi:10.25251/esydg329","doi":"https://doi.org/10.25251/esydg329","is_oa":true,"landing_page_url":"https://doi.org/10.25251/esydg329","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/esydg329","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5139694975","display_name":"Amy Paller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amy Paller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065570109","display_name":"Vimal H. Prajapati","orcid":"https://orcid.org/0000-0002-8315-2522","observed_orcids":["https://orcid.org/0000-0002-8315-2522"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vimal Prajapati","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015290431","display_name":"Ulrike Blume\u2010Peytavi","orcid":"https://orcid.org/0000-0003-3528-3752","observed_orcids":["https://orcid.org/0000-0003-3528-3752"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ulrike Blume-Peytavi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019049232","display_name":"Val\u00e9ria Aoki","orcid":"https://orcid.org/0000-0003-4256-4413","observed_orcids":["https://orcid.org/0000-0003-4256-4413"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valeria Aoki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5135865292","display_name":"Lin Ma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lin Ma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161414556","display_name":"Lara Wine Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lara Wine Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161406294","display_name":"Vera Beckers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vera Beckers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006579778","display_name":"Gweneth Levy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gweneth Levy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161385687","display_name":"Shilpa Goel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shilpa Goel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020593835","display_name":"Henrique D. Teixeira","orcid":"https://orcid.org/0000-0001-5488-3556","observed_orcids":["https://orcid.org/0000-0001-5488-3556"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Henrique Teixeira","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5160193017","display_name":"Alan Irvine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alan Irvine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s859","last_page":"s859"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9312999844551086},{"id":"https://openalex.org/C2779824493","wikidata":"https://www.wikidata.org/wiki/Q5315925","display_name":"Dupilumab","level":3,"score":0.8690999746322632},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7685999870300293},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.5828999876976013},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48420000076293945},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.41290000081062317},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3806999921798706},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3463999927043915},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3361999988555908},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.328000009059906},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.32359999418258667},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3151000142097473},{"id":"https://openalex.org/C128057223","wikidata":"https://www.wikidata.org/wiki/Q420566","display_name":"Calcineurin","level":3,"score":0.3050000071525574},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.26980000734329224},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.2653000056743622},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.2554999887943268}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/esydg329","doi":"https://doi.org/10.25251/esydg329","is_oa":true,"landing_page_url":"https://doi.org/10.25251/esydg329","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/esydg329","doi":"https://doi.org/10.25251/esydg329","is_oa":true,"landing_page_url":"https://doi.org/10.25251/esydg329","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W3164705475"],"related_works":[],"abstract_inverted_index":{"Introduction":[0],"&":[1,78],"Objectives":[2],"While":[3],"phase":[4,52],"3":[5,53],"studies":[6],"established":[7],"the":[8,41,70,176,238,248,257,259,266,296,300,308,344,435,442,455],"safety":[9,458],"and":[10,27,37,103,243,276,298,439,457,485],"efficacy":[11,261,303,456],"of":[12,21,67,72,85,115,135,158,166,173,184,203,241,251,268,310,330,459],"upadacitinib":[13],"(UPA),":[14],"an":[15,48,90,153,161,198,211,224],"oral":[16,212,225],"JAK":[17],"inhibitor,":[18],"for":[19,69,188,219,234,244,318,347,363,411,441],"treatment":[20,71,92,339],"atopic":[22],"dermatitis":[23],"(AD)":[24],"in":[25,40,59,273,283,337,463,478],"adults":[26],"adolescents,1-3":[28],"it":[29],"is":[30,47,83,191,263,305,386],"important":[31],"to":[32,57,63,74,96,100,111,119,130,151,264,306,353,373,380,398,461,467,473],"evaluate":[33,476],"its":[34],"safety,":[35],"efficacy,":[36],"optimal":[38],"dosing":[39],"younger":[42],"pediatric":[43],"population.":[44],"START":[45,80,450],"UP":[46,81,451],"ongoing":[49,449],"open-label,":[50],"efficacy-assessor-blinded,":[51],"study":[54,444,452],"comparing":[55],"UPA":[56,159,167,204,206,242,287,348,368,374,381,392,399,417,420,460,477],"dupilumab":[58,185,190,342,462,481],"children":[60,464],"from":[61,328],"2":[62,110,332,466],"<":[64,112,468],"12":[65,113,245,469],"years":[66,114,470],"age":[68,116],"moderate":[73,118,472],"severe":[75,120,474],"AD.":[76,121],"Materials":[77],"Methods":[79],"(NCT06461897)":[82],"comprised":[84],"a":[86,104,170,215,326,405],"35-day":[87],"screening":[88],"period,":[89],"open-label":[91],"period":[93],"(week":[94],"0":[95,322],"160;":[97],"assessor-blinded":[98],"up":[99],"week":[101,281,335,403],"16)":[102],"follow-up":[105,440],"period.":[106],"Eligible":[107],"patients":[108,125,144,179,220,269,284,311,356,390,412],"are":[109,445],"with":[117,126,180,197,286,290,293,325,341,377,416,428,471],"In":[122,175,253,295],"one":[123],"cohort,":[124,178],"inadequate":[127],"response":[128],"(IR)":[129],"systemic":[131],"therapy":[132],"or":[133,142,169,182,187,323,419,480],"intolerance":[134,183],"topical":[136,139],"corticosteroids":[137],"and/or":[138],"calcineurin":[140],"inhibitors":[141],"dupilumab-exposed":[143],"without":[145],"IR":[146,181],"will":[147,194,207,231,360,408,425,431,453],"be":[148,195,208,232,361,409,426,432],"randomized":[149],"3:1:1":[150],"receive":[152],"adult":[154,162,199],"equivalent":[155,163,200],"weight-based":[156,164,201],"dose":[157,165,172,202,240,250,364,406,423,487],"15mg,":[160],"7.5mg,":[168],"label-indicated":[171],"dupilumab.":[174,252,294,429],"second":[177],"(dupilumab-IR)":[186],"whom":[189],"medically":[192,482],"inadvisable":[193,483],"treated":[196,285,292],"15mg.":[205,349],"administered":[209],"as":[210,223,343],"solution":[213],"twice":[214],"day":[216],"(BID)":[217],"or,":[218],"\u2265":[221,331],"30kg,":[222],"tablet":[226],"once":[227],"daily":[228],"(QD).":[229],"Patients":[230],"followed":[233],"30":[235,382,400],"days":[236],"after":[237,247],"last":[239,249],"weeks":[246],"countries":[254],"other":[255],"than":[256],"USA,":[258],"primary":[260],"objective":[262,304],"assess":[265,307,486],"proportion":[267,309],"achieving":[270,312,358],"\u226575%":[271],"improvement":[272],"Eczema":[274],"Area":[275],"Severity":[277],"Index":[278],"(EASI-75)":[279],"at":[280,334],"16":[282,336],"15mg":[288,418],"compared":[289],"those":[291,366],"USA":[297],"China,":[299],"primary,":[301],"descriptive":[302],"validated":[313],"Investigator":[314],"Global":[315],"Assessment":[316],"scale":[317],"Atopic":[319],"Dermatitis":[320],"(vIGA-AD)":[321],"1":[324],"reduction":[327,407],"baseline":[329],"points":[333],"each":[338],"group,":[340],"reference":[345],"arm":[346],"From":[350],"Week":[351,354],"20":[352],"40,":[355],"not":[357,388],"EASI-75":[359,385],"eligible":[362],"escalation:":[365],"on":[367,391],"7.5":[369],"mg":[370,383,394],"may":[371,395],"increase":[372],"15":[375,393],"mg,":[376],"further":[378],"escalation":[379],"if":[384],"still":[387],"achieved;":[389],"escalate":[396],"directly":[397],"mg.":[401],"At":[402],"52,":[404],"mandatory":[410],"who":[413],"achieve":[414],"EASI-90":[415],"30mg.":[421],"No":[422],"changes":[424],"permitted":[427],"Safety":[430],"assessed":[433],"throughout":[434],"study.":[436],"Results":[437],"Recruitment":[438],"START-UP":[443],"ongoing.":[446],"Conclusion":[447],"The":[448],"compare":[454],"aged":[465],"AD,":[475],"dupilumab-IR":[479],"patients,":[484],"optimization.":[488]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}